Click here to get full coverage on Autolus Therapeutics plc (NASDAQ:AUTL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st

Autolus Therapeutics plc (NASDAQ:AUTL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates  simplywall.st

Autolus Therapeutics plc (NASDAQ:AUTL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st

Click here to get full coverage on Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake - Stock Titan

Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake  Stock Titan

Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake - Stock Titan

Click here to get full coverage on AUTOLUS THERAPEUTICS ($AUTL) Releases Q2 2026 Earnings - Quiver Quantitative

AUTOLUS THERAPEUTICS ($AUTL) Releases Q2 2026 Earnings  Quiver Quantitative

AUTOLUS THERAPEUTICS ($AUTL) Releases Q2 2026 Earnings - Quiver Quantitative

Click here to get full coverage on Autolus Therapeutics (AUTL) Earnings Date and Reports 2026 $AUTL - MarketBeat

Autolus Therapeutics (AUTL) Earnings Date and Reports 2026 $AUTL  MarketBeat

Autolus Therapeutics (AUTL) Earnings Date and Reports 2026 $AUTL - MarketBeat

Click here to get full coverage on Autolus Therapeutics (AUTL) Stock Sees Split Analyst Revisions After Early Aucatyzl Launch Signals - Yahoo Finance

Autolus Therapeutics (AUTL) Stock Sees Split Analyst Revisions After Early Aucatyzl Launch Signals  Yahoo Finance

Autolus Therapeutics (AUTL) Stock Sees Split Analyst Revisions After Early Aucatyzl Launch Signals - Yahoo Finance

Click here to get full coverage on AUTL: Q2 2026 revenue jumped 119% year-over-year, with gross margin up to 55% and guidance raised - TradingView

AUTL: Q2 2026 revenue jumped 119% year-over-year, with gross margin up to 55% and guidance raised  TradingView

AUTL: Q2 2026 revenue jumped 119% year-over-year, with gross margin up to 55% and guidance raised - TradingView

Click here to get full coverage on Autolus Therapeutics plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AUTL) 2026-08-11 - Seeking Alpha

Autolus Therapeutics plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AUTL) 2026-08-11  Seeking Alpha

Autolus Therapeutics plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AUTL) 2026-08-11 - Seeking Alpha

Click here to get full coverage on Autolus Therapeutics (AUTL) Tops Q2 EPS by 8c - StreetInsider

Autolus Therapeutics (AUTL) Tops Q2 EPS by 8c  StreetInsider

Autolus Therapeutics (AUTL) Tops Q2 EPS by 8c - StreetInsider

Click here to get full coverage on Equities Analysts Offer Predictions for AUTL Q3 Earnings - MarketBeat

Equities Analysts Offer Predictions for AUTL Q3 Earnings  MarketBeat

Equities Analysts Offer Predictions for AUTL Q3 Earnings - MarketBeat

Click here to get full coverage on How The Autolus Therapeutics (AUTL) Investment Story Is Evolving With A Steady Analyst Outlook - Yahoo Finance

How The Autolus Therapeutics (AUTL) Investment Story Is Evolving With A Steady Analyst Outlook  Yahoo Finance

How The Autolus Therapeutics (AUTL) Investment Story Is Evolving With A Steady Analyst Outlook - Yahoo Finance

Click here to get full coverage on AUTL: Q2 2026 revenue up 119% year-over-year, with gross margin reaching 55% and guidance raised - TradingView

AUTL: Q2 2026 revenue up 119% year-over-year, with gross margin reaching 55% and guidance raised  TradingView

AUTL: Q2 2026 revenue up 119% year-over-year, with gross margin reaching 55% and guidance raised - TradingView

Click here to get full coverage on AUTL: Q2 2026 revenue up 119% year-over-year, gross margin at 55%, FY guidance raised - TradingView

AUTL: Q2 2026 revenue up 119% year-over-year, gross margin at 55%, FY guidance raised  TradingView

AUTL: Q2 2026 revenue up 119% year-over-year, gross margin at 55%, FY guidance raised - TradingView

Click here to get full coverage on AUTL Aug 2026 0.500 call (AUTL260821C00000500) Stock Price, News, Quote & History - Yahoo! Finance Canada

AUTL Aug 2026 0.500 call (AUTL260821C00000500) Stock Price, News, Quote & History  Yahoo! Finance Canada

AUTL Aug 2026 0.500 call (AUTL260821C00000500) Stock Price, News, Quote & History - Yahoo! Finance Canada

Click here to get full coverage on Autolus Therapeutics (NASDAQ:AUTL) Trading Down 7% - Here's Why - MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Trading Down 7% - Here's Why  MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Trading Down 7% - Here's Why - MarketBeat

Click here to get full coverage on AUTL: Q2 revenue and margin surged, guidance raised, and cash runway extended with new financing - TradingView

AUTL: Q2 revenue and margin surged, guidance raised, and cash runway extended with new financing  TradingView

AUTL: Q2 revenue and margin surged, guidance raised, and cash runway extended with new financing - TradingView

Click here to get full coverage on Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now  Yahoo Finance

Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Click here to get full coverage on Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings - MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings  MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings - MarketBeat

Click here to get full coverage on Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Beats Estimates By $0.06 EPS  MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat

Click here to get full coverage on How The Narrative On Autolus Therapeutics (AUTL) Is Shifting After Analyst Target Resets - Yahoo Finance

How The Narrative On Autolus Therapeutics (AUTL) Is Shifting After Analyst Target Resets  Yahoo Finance

How The Narrative On Autolus Therapeutics (AUTL) Is Shifting After Analyst Target Resets - Yahoo Finance

Click here to get full coverage on Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue Builds - Yahoo Finance

Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue Builds  Yahoo Finance

Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue Builds - Yahoo Finance

Click here to get full coverage on Autolus Therapeutics Q2 Earnings Call Highlights - Yahoo Finance

Autolus Therapeutics Q2 Earnings Call Highlights  Yahoo Finance

Autolus Therapeutics Q2 Earnings Call Highlights - Yahoo Finance

Click here to get full coverage on Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance

Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?  Yahoo Finance

Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance

Click here to get full coverage on Is Autolus Therapeutics (AUTL) One of the Best Biotech Penny Stocks to Buy in 2026? - Yahoo Finance

Is Autolus Therapeutics (AUTL) One of the Best Biotech Penny Stocks to Buy in 2026?  Yahoo Finance

Is Autolus Therapeutics (AUTL) One of the Best Biotech Penny Stocks to Buy in 2026? - Yahoo Finance

Click here to get full coverage on Autolus Therapeutics: Navigating A Bumpy 2026 (NASDAQ:AUTL) - Seeking Alpha

Autolus Therapeutics: Navigating A Bumpy 2026 (NASDAQ:AUTL)  Seeking Alpha

Autolus Therapeutics: Navigating A Bumpy 2026 (NASDAQ:AUTL) - Seeking Alpha

Click here to get full coverage on Autolus Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat

Autolus Therapeutics Q2 2026 Earnings Call Transcript  MarketBeat

Autolus Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat

Click here to get full coverage on How The Autolus Therapeutics (AUTL) Narrative Is Shifting With Recalibrated Targets And Fair Value - Yahoo Finance

How The Autolus Therapeutics (AUTL) Narrative Is Shifting With Recalibrated Targets And Fair Value  Yahoo Finance

How The Autolus Therapeutics (AUTL) Narrative Is Shifting With Recalibrated Targets And Fair Value - Yahoo Finance

Click here to get full coverage on Autolus Sets Aug. 11 Webcast for Q2 Results and Business Update - Stock Titan

Autolus Sets Aug. 11 Webcast for Q2 Results and Business Update  Stock Titan

Autolus Sets Aug. 11 Webcast for Q2 Results and Business Update - Stock Titan

Click here to get full coverage on Autolus Therapeutics (AUTL) to Cut Workforce by 13% While Doubling 2026 Manufacturing Capacity - Yahoo Finance

Autolus Therapeutics (AUTL) to Cut Workforce by 13% While Doubling 2026 Manufacturing Capacity  Yahoo Finance

Autolus Therapeutics (AUTL) to Cut Workforce by 13% While Doubling 2026 Manufacturing Capacity - Yahoo Finance

Click here to get full coverage on Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now? - Yahoo Finance

Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now?  Yahoo Finance

Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now? - Yahoo Finance

Click here to get full coverage on AUTL Forecast — Price Target — Prediction for 2027 - TradingView

AUTL Forecast — Price Target — Prediction for 2027  TradingView

AUTL Forecast — Price Target — Prediction for 2027 - TradingView

Click here to get full coverage on Does Autolus Therapeutics (AUTL) Pairing AUCATZYL Approvals With Revenue Guidance Redefine Its Long-Term Story? - Yahoo Finance

Does Autolus Therapeutics (AUTL) Pairing AUCATZYL Approvals With Revenue Guidance Redefine Its Long-Term Story?  Yahoo Finance

Does Autolus Therapeutics (AUTL) Pairing AUCATZYL Approvals With Revenue Guidance Redefine Its Long-Term Story? - Yahoo Finance

Click here to get full coverage on Renaissance Technologies LLC Has $3.17 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat

Renaissance Technologies LLC Has $3.17 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL  MarketBeat

Renaissance Technologies LLC Has $3.17 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat

Click here to get full coverage on Autolus will post quarterly results before market open on May 14 - Stock Titan

Autolus will post quarterly results before market open on May 14  Stock Titan

Autolus will post quarterly results before market open on May 14 - Stock Titan

Click here to get full coverage on Autolus plans 13% job cuts while doubling 2026 manufacturing - Stock Titan

Autolus plans 13% job cuts while doubling 2026 manufacturing  Stock Titan

Autolus plans 13% job cuts while doubling 2026 manufacturing - Stock Titan

Click here to get full coverage on Autolus Therapeutics (NASDAQ:AUTL) Earns "Buy" Rating from HC Wainwright - MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Earns "Buy" Rating from HC Wainwright  MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Earns "Buy" Rating from HC Wainwright - MarketBeat

Click here to get full coverage on T cell therapy company Autolus schedules Mar. 27 results call - Stock Titan

T cell therapy company Autolus schedules Mar. 27 results call  Stock Titan

T cell therapy company Autolus schedules Mar. 27 results call - Stock Titan

Click here to get full coverage on Autolus Therapeutics (NASDAQ:AUTL) Rating Increased to Sell at Wall Street Zen - MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Rating Increased to Sell at Wall Street Zen  MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Rating Increased to Sell at Wall Street Zen - MarketBeat

Click here to get full coverage on Autolus targets positive gross margin in 2026 as UK launch starts - Stock Titan

Autolus targets positive gross margin in 2026 as UK launch starts  Stock Titan

Autolus targets positive gross margin in 2026 as UK launch starts - Stock Titan

Click here to get full coverage on Autolus Therapeutics plc (AUTL) Stock Analysis: Biotechnology Innovator with 333% Potential Upside - DirectorsTalk Interviews

Autolus Therapeutics plc (AUTL) Stock Analysis: Biotechnology Innovator with 333% Potential Upside  DirectorsTalk Interviews

Autolus Therapeutics plc (AUTL) Stock Analysis: Biotechnology Innovator with 333% Potential Upside - DirectorsTalk Interviews

Click here to get full coverage on Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy? - MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy?  MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy? - MarketBeat

Click here to get full coverage on Autolus Therapeutics plc (AUTL) Stock Analysis: Exploring a 458.82% Upside Potential in the Biotech Sector - DirectorsTalk Interviews

Autolus Therapeutics plc (AUTL) Stock Analysis: Exploring a 458.82% Upside Potential in the Biotech Sector  DirectorsTalk Interviews

Autolus Therapeutics plc (AUTL) Stock Analysis: Exploring a 458.82% Upside Potential in the Biotech Sector - DirectorsTalk Interviews

Click here to get full coverage on Leukemia study finds 59% remission with obe-cel in high-risk adults - Stock Titan

Leukemia study finds 59% remission with obe-cel in high-risk adults  Stock Titan

Leukemia study finds 59% remission with obe-cel in high-risk adults - Stock Titan

Click here to get full coverage on AUTL Dec 2026 2.000 call (AUTL261218C00002000) interactive stock chart - Yahoo Finance UK

AUTL Dec 2026 2.000 call (AUTL261218C00002000) interactive stock chart  Yahoo Finance UK

AUTL Dec 2026 2.000 call (AUTL261218C00002000) interactive stock chart - Yahoo Finance UK

Click here to get full coverage on Autolus Therapeutics (NASDAQ:AUTL) Trading Down 0.7% - Time to Sell? - MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Trading Down 0.7% - Time to Sell?  MarketBeat

Autolus Therapeutics (NASDAQ:AUTL) Trading Down 0.7% - Time to Sell? - MarketBeat

Click here to get full coverage on Why is Autolus Therapeutics plc (AUTL) One of the Best Stocks Under $5 With Highest Upside Potential? - Yahoo Finance

Why is Autolus Therapeutics plc (AUTL) One of the Best Stocks Under $5 With Highest Upside Potential?  Yahoo Finance

Why is Autolus Therapeutics plc (AUTL) One of the Best Stocks Under $5 With Highest Upside Potential? - Yahoo Finance

Click here to get full coverage on Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Moderate Buy" by Brokerages  MarketBeat

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Click here to get full coverage on Autolus CEO Christian Itin joins June 30 cell therapy fireside chat - Stock Titan

Autolus CEO Christian Itin joins June 30 cell therapy fireside chat  Stock Titan

Autolus CEO Christian Itin joins June 30 cell therapy fireside chat - Stock Titan

Click here to get full coverage on Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials - simplywall.st

Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials  simplywall.st

Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials - simplywall.st

Click here to get full coverage on Autolus Therapeutics (AUTL) Releases Q4 2025 Earnings: Revenue Soars but Net Loss Widens - Quiver Quantitative

Autolus Therapeutics (AUTL) Releases Q4 2025 Earnings: Revenue Soars but Net Loss Widens  Quiver Quantitative

Autolus Therapeutics (AUTL) Releases Q4 2025 Earnings: Revenue Soars but Net Loss Widens - Quiver Quantitative

Click here to get full coverage on 22 Autolus employees get four-year stock options on 113,650 ADS - Stock Titan

22 Autolus employees get four-year stock options on 113,650 ADS  Stock Titan

22 Autolus employees get four-year stock options on 113,650 ADS - Stock Titan

Click here to get full coverage on Autolus Therapeutics Reports Preliminary Q2 2026 AUCATZYL Revenue of About $45 Million, Raises FY 2026 Sales Guidance and Secures $75 Million Financing - Quiver Quantitative

Autolus Therapeutics Reports Preliminary Q2 2026 AUCATZYL Revenue of About $45 Million, Raises FY 2026 Sales Guidance and Secures $75 Million Financing  Quiver Quantitative

Autolus Therapeutics Reports Preliminary Q2 2026 AUCATZYL Revenue of About $45 Million, Raises FY 2026 Sales Guidance and Secures $75 Million Financing - Quiver Quantitative

Click here to get full coverage on Autolus Raises AUCATZYL Outlook, Secures New Credit Facility - The Globe and Mail

Autolus Raises AUCATZYL Outlook, Secures New Credit Facility  The Globe and Mail

Autolus Raises AUCATZYL Outlook, Secures New Credit Facility - The Globe and Mail

Click here to get full coverage on The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26% - simplywall.st

The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%  simplywall.st

The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26% - simplywall.st

Click here to get full coverage on AUTL: Expanding CAR T-cell therapy demonstrates robust efficacy, safety, and broadening market reach - TradingView

AUTL: Expanding CAR T-cell therapy demonstrates robust efficacy, safety, and broadening market reach  TradingView

AUTL: Expanding CAR T-cell therapy demonstrates robust efficacy, safety, and broadening market reach - TradingView

Click here to get full coverage on Autolus Therapeutics Q1 Earnings Call Highlights - Yahoo Finance

Autolus Therapeutics Q1 Earnings Call Highlights  Yahoo Finance

Autolus Therapeutics Q1 Earnings Call Highlights - Yahoo Finance

Click here to get full coverage on Autolus shares rise 3% on Q2 beat, raised revenue guidance - Investing.com

Autolus shares rise 3% on Q2 beat, raised revenue guidance  Investing.com

Autolus shares rise 3% on Q2 beat, raised revenue guidance - Investing.com

Click here to get full coverage on Autolus Therapeutics (AUTL) director granted options and 31,667 RSUs - Stock Titan

Autolus Therapeutics (AUTL) director granted options and 31,667 RSUs  Stock Titan

Autolus Therapeutics (AUTL) director granted options and 31,667 RSUs - Stock Titan

Click here to get full coverage on Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts (AUTL) - Seeking Alpha

Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts (AUTL)  Seeking Alpha

Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts (AUTL) - Seeking Alpha

Click here to get full coverage on Market Review 312: Our Next Four Picks For August - CAR-T, Psychedelics, Health Insurance, Radiopharma - Seeking Alpha

Market Review 312: Our Next Four Picks For August - CAR-T, Psychedelics, Health Insurance, Radiopharma  Seeking Alpha

Market Review 312: Our Next Four Picks For August - CAR-T, Psychedelics, Health Insurance, Radiopharma - Seeking Alpha

Click here to get full coverage on Price to book forward of Autolus Therapeutics plc – NASDAQ:AUTL - TradingView

Price to book forward of Autolus Therapeutics plc – NASDAQ:AUTL  TradingView

Price to book forward of Autolus Therapeutics plc – NASDAQ:AUTL - TradingView

Click here to get full coverage on AUTL: Strong commercial growth and pipeline progress, with high remission rates and expanding indications - TradingView

AUTL: Strong commercial growth and pipeline progress, with high remission rates and expanding indications  TradingView

AUTL: Strong commercial growth and pipeline progress, with high remission rates and expanding indications - TradingView

Click here to get full coverage on AUTL: Strong revenue growth, clinical progress, and operational efficiency drive future value - TradingView

AUTL: Strong revenue growth, clinical progress, and operational efficiency drive future value  TradingView

AUTL: Strong revenue growth, clinical progress, and operational efficiency drive future value - TradingView

Click here to get full coverage on AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK - Stocktwits

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK  Stocktwits

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK - Stocktwits

Click here to get full coverage on AUTL: Q1 2026 revenue surged, gross margin turned positive, and cost-saving measures were implemented - TradingView

AUTL: Q1 2026 revenue surged, gross margin turned positive, and cost-saving measures were implemented  TradingView

AUTL: Q1 2026 revenue surged, gross margin turned positive, and cost-saving measures were implemented - TradingView

Click here to get full coverage on AUTL: Q1 2026 revenue jumped to $26.2M, with strong AUCATZYL uptake and margin improvement initiatives - TradingView

AUTL: Q1 2026 revenue jumped to $26.2M, with strong AUCATZYL uptake and margin improvement initiatives  TradingView

AUTL: Q1 2026 revenue jumped to $26.2M, with strong AUCATZYL uptake and margin improvement initiatives - TradingView

Click here to get full coverage on AUTL: Product revenue surged 192% year-over-year, with cost controls and a major workforce reduction underway - TradingView

AUTL: Product revenue surged 192% year-over-year, with cost controls and a major workforce reduction underway  TradingView

AUTL: Product revenue surged 192% year-over-year, with cost controls and a major workforce reduction underway - TradingView

Click here to get full coverage on AUTL: AUCATZYL shows high efficacy and safety, driving growth and broader access in ALL therapy - TradingView

AUTL: AUCATZYL shows high efficacy and safety, driving growth and broader access in ALL therapy  TradingView

AUTL

Price Chart

Key Statistics

Technicals

About AUTL

Latest News

Autolus Therapeutics plc (NASDAQ:AUTL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st

Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake - Stock Titan

AUTOLUS THERAPEUTICS ($AUTL) Releases Q2 2026 Earnings - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers